SANUWAVE Health Inc (SNWV) 2024 Q2 法說會逐字稿

Good day, everyone, and welcome to SANUWAVE announces highest quarterly revenue in company history Q2 2024 Results. (Operator Instructions). Later you will have the opportunity to ask questions during the question-and-answer session. (Operator Instructions). Please note that this call may be recorded. (Operator Instructions)

It is now my pleasure to turn the conference over to Morgan Frank, CEO.

Welcome to SANUWAVE's Second Quarter 2024 Earnings Call. As many of you probably noticed, our Form 10-Q was filed with the SEC Monday night. Our earnings release was issued this morning and our updated presentation is made available on the website in our Investors section. Please refer to that during this presentation. Joining me on the call is Peter Sorensen, our CFO. And after the call, we will open up for Q&A.

So before we get going, let me go through the obligatory forward-looking statements disclaimer. This call may contain forward-looking statements such as statements regarding to future financial results, production expectations and constraints, plans for future business development activities. Investors are cautioned that any such forward-looking statements are not guarantees of future performance, and all risks and uncertainties, many of which are beyond the company's ability to control. Description of these risks and uncertainties and other factors that could affect our financial results is included in the AEC filings. Actual results may differ materially from those projected in the forward-looking statements, and the company undertakes no obligation to update any forward-looking statements.

As a reminder, our discussion today will include non-GAAP numbers. Reconciliations between our GAAP and non-GAAP results can be found in our recently filed 10-Q for the quarter ended June 30, 2024.

Okay. That's it. So last conference call, we spoke about the higher growth rates in Q1 being sustainable going forward. And we believe that we can get our gross margins to stabilize in the mid-70s in the near term. We are obviously very pleased to have hit both of these targets once more putting up revenue growth figures north of 50%, 53% to be precise for Q2 2024 and gross margins of 73% despite some costs associated with standing up our new contract manufacturers.

So hitting record quarterly revenue levels for the company despite the first half generally being seasonally softer in the second half, was really strong performance by the company and doing this while also achieving operating and adjusted EBITDA positivity despite some additional costs in the quarter around the merger, which we terminated and the manufacturing costs that I just mentioned, I think really starts to drive home the potential for our business and for this business model.

We are going to continue our mantra of rapid profitable growth as our guiding principle and we are extremely excited about the traction and the success that we're seeing in our markets. And this has led us to increase our quarterly revenue growth guidance from 45% to 55% in each of Q1 and Q2 and raise that up to 65% to 75% versus prior year for Q3 2024.

We've been adding to our sales force and our commercial operations team. We've been stepping up our manufacturing capacity as well as we prepare for what we aim to make a breakout second half for SANUWAVE. Ultimate systems sold in the quarter were up 47% from Q2 2023, and we ended the quarter with 788 active systems in the field.

Revenue from the UltraMIST product line in Q2 2024 increased 62% year-on-year and consumable applicators revenue, the razorblade to our razor increased 67% in Q2 2024 versus Q2 2023 and 15% sequentially from our prior record quarter of Q1 2024.

Both categories showed revenue growth in excess of unit growth due to strong pricing and applicators continue to benefit a larger user base that we have in the field. We're particularly pleased with the linearity we've been seeing in applicator sales, which can be seen on page 6 of Q2 business update deck on our website.

Applicator revenues are roughly 65% of total revenues in Q2, which is, I mean, honestly, still a little bit higher than we've been aiming for. Our aim is to get this number down into the 55% area. Obviously, not because we expect applicator sales to wane, but because we are looking to sell more systems and to grow our user base setting the stage for even more future growth.

We believe this process is well underway and as of the time of this call, we've already sold more systems in Q3 2024 than we sold in all of Q3 last year. So we continue to focus on building a robust pipeline of large and midsized customers to serve the significant unmet needs in the wound care space and our initiatives to more deeply engage particularly with skilled nursing, long-term care and the mobile wound systems that are focused on these markets are starting to bear some real fruit and to lead not just to more customers and customer uptake.

But are really starting to help structure and redefine how providers think about patients, complex wounds or even pressure injuries in bed sores and we believe this more holistic behavior -- this more holistic engagement is going to lead to a better business for us and for improved outcomes for our patients as we continue to facilitate these care to the edge philosophies of treating patients where they are and to do so early, often and effectively.

I'm now going to turn the call over to Peter Sorensen, our CFO, to run you through the financial results.

Thank you, Morgan. And indeed was an exciting quarter for Sanuwave as we achieved all-time record high quarterly revenues. We added over $8 million to our stockholders' equity, increasing our bottom line and paying off long-standing debt liabilities, and we continue to execute on our goal of rapid profitable growth.

Revenue for the three months ended June 30, 2024, totaled $7.2 million, an increase of 53% as compared to $4.7 million for the same period of 2023. This growth is within our previous guidance range of 45% to 55%, as previously discussed by Morgan.

Gross margin as a percentage of revenue amounted to 73% for the three months ended June 30, 2024, versus 74% for the same period last year. For the three months ended June 30, 2024, operating income totaled $2 million, which is an improvement of $1.1 million compared to the same period last year which aligns with our continued initiative to drive towards profitable growth and manage spend effectively.

Operating expenses for the three months ended June 30, 2024, amounted to $3.2 million compared to $2.5 million for the three months ended June 30, 2023, an increase of $706,000. However, operating expenses as a percentage of revenue dropped to 62% in Q2 2024 versus 73% in Q2 2023, as well as there is a onetime adjustment in Q2 2023 to release historical accruals for $1.3 million.

Net income for the three months ended June 30, 2024, was $6.6 million compared to a net loss of $7.3 million for the same period in 2023. The increase in net income was primarily due to a change in the fair value of derivative liabilities, a gain on extinguishment of debt and an increase in operating income.

Adjusted EBITDA for the three months ended June 30, 2024, was $1.5 million versus $171,000 for the same period last year, an improvement of $1.3 million. Sanuwave continues to execute its financial strategy to improve operational profitability and manage operating expenses.

Total current assets amounted to $8.7 million as of June 30, 2024, versus $9.8 million as of December 31, 2023. Cash and cash equivalents totaled $2.5 million as of June 30, 2020.

We thank you for the continued support of Sanuwave, and I'll now transfer the call back to Morgan.

Okay. So on to other matters. The company terminated its merger with SEPA during the quarter. We did this because there appeared to be no path to acquiring a national securities exchange listing for the post-merger entity. So the company deemed that it was no longer dealing the best interest to shareholders. The good thing is that our economics business model has improved a great deal over the last 12 months. And we now find ourselves in a position of having sufficient capital to run the business and move forward without the dilution or the complexity of leaseback merger.

Since this termination, we've been taking steps to simplify and improve our capital structure. So we paid off piece of noncompliant debt at a significant discount. We're also seeking to execute a reverse stock split to reduce our share count and we're going to use this reverse split as a trigger for a note warrant exchange similar to the one -- really, I got to go to the one we were using or that we had proposed under the idn merger and that, that will really simplify our cap stack and improve our shareholders' equity.

At this time, we have received shareholder approval for the reverse split, and we have agreed -- we've received agreement on the exchange from 100% of outstanding note and warrant holders within the within the future promissory note classes issued between August of 2022 at present. So we're currently assessing the split ratios and the best timing on this plan, but I think it's reasonable to assume this will occur in the near future.

I know that reverse splits have something of a bad history, but this is generally because they tend to occur companies fundamentals are poor and deteriorating, and that's simply not the case here. We have spoken in the past about being about 2024 being a breakout year for Sanuwave and having all the pieces in place that we need to execute. We are more convinced than ever that this can be so, and simplifying our cap structure reducing our share count and getting our stock price up to a respectable integer is the next step in getting this company to a point where we can value for our business and not our cap structure.

So I mean we're building for the long term here and our growth is accelerating. This team is keen, hungry for more and really looking to go make it happen. So I just want to thank everyone at Sanuwave for all of their hard work and blood, sweat and tears of getting us here and taking us forward. None of this happens by itself, and it's been an amazing thing to be a part of. And by all indications, the best is yet come.

So with that, I think that's the end of our prepared comments. So why don't I turn this back over to the operator, and we can queue up questions.

(Operator Instructions) [Adam Gosola], private investor.

I have a number of questions. My first I can politely ask, as we chat percentages, that's all quite interesting. Can we talk actual number and acquisition units or new customers? And what each unit per se, say at the UltraMIST or the separation of Sanuwave and how each of those units directly impact the bottom line, cost of acquisition, cost to implement and then perhaps chat how these mechanisms are now returning back to the company? That's my first question, please, and thank you.

So I mean in terms of the -- so I guess to start off with, as we sell a system, we have not been releasing the exact ASPs we're getting on a quarterly basis. The list price on an UltraMIST system is about $35,000. So then we're not capturing full list price, but we're capturing a great deal more of it than we once did. We ultimately view this as sort of a razor-razorblade model, where the goal is to get the system out in the hands of the customer and generate revenue from individual applicator sales associated with each procedure that's performed. We track this internally and refer to it as tax rate, which is how many 12 -- how many cases of 12 applicators does the system use per week in the field.

In terms of systems, so that's a number that, obviously, we manage to very closely but also haven't shared with the Street. I mean, obviously, what we can share is that the amount of consumables revenue has been going up very significantly across quarters and it's been sort of leading the -- it's the leading source of the company's revenue and it has been leading a lot of the company's growth.

So in terms of what does it cost to get a system out into the field, we have two different sales channels, right? We use, I guess, really three. We have direct sales force, right? And we had -- I mean we began this year at only about two reps. We've ramped that up to more like nine right about now.

We also use a series of distributors on a 10-99 basis. These distributors are not compensated unless they place units and if so, are paid commissions on the systems that they sell. And the last channel being our internal sort of noncommissioned commercial sales operation that works both like sort of a business development and an internal sales force. And when you break it all down, I don't know that I have a percentage for you on what we're spending on that customer cost of acquisition across everything.

Peter, do you have a thought on that?

Yes, I think it really areas across channels. So I don't have an exact estimate per channel. But I think something in the 10% to 15% range is probably of overall sales is probably a pretty reasonable. It's probably a pretty reasonable range to consider.

You had several questions. Was there anything I didn't get to?

Yes. So you began to touch on one of the points, and I won't be intrusive or hold you accountable to unit numbers if that's something you haven't shared with the Street yet. So you mentioned sales and sales force. And one of the things that I happen to know is trafficking on your website myself is that I believe your website is not fully optimized, where if someone is going to your website and clicking about us, you can track and monitor your data. And I'm not talking through Google, I'm talking through your own website, you can find out who and pretty much right down the location and IP address and even potentially a business address and generate a sales lead.

That's something that is very prevalent in today's society. And I noticed I don't know how you're obtaining your customers. I do know it's a captive audience. There are only so many people involved in wound care. I know that you guys market and go to all the events I've tried to make a few when Mr. Richardson was hosting them. I wasn't able to make them, I believe in the company.

How is it that you're generating more sales in this environment? I noticed that a publicist, sometimes, in the right direction, can help generate the needed attention. And given its venue where the stock trades, there is very little attention given to the story. If there was even an ounce of attention paid to the story, we wouldn't be trading at $0.05. Can you comment on that?

Well, I think this is part of the reason why we're interested in cleaning up the cap structure, right? I think that where the -- we've been seeking first to get the company's fundamentals together. Now that we have them together and have a story, the fundamentals will ultimately out so long if you can get yourself into a position where the company is being valued for its business rather than its cap structure.

With the current note warrant structure, it becomes difficult to even assess what the company's share count is and to realize what it -- you realize how low its market cap actually is. There are also far fewer investors, I think, that will look at a stock valued in this ranch, and it's part of why we want to get our stock price up to something that looks like a respectable imager.

I mean, as you probably know, I have 25 years of or, I guess, really now 30 years of cap markets experience. So -- (multiple speakers) thoughts on -- and I think you're going to be seeing a lot more outreach towards the Street once we have a stock that more people would be comfortable looking at?

Right, about $5 because the longs are restricted, a number of accounts, retail, there are so many restrictions to access a pink sheet bulletin board or now [QQQ].

(Operator Instructions). We show no further questions at this time. I will turn the call back to management for closing or additional remarks.

Great. Thank you very much, and thank you, everyone, for joining us, and we will speak to you next quarter.

This does conclude today's program. Thank you for your participation. You may disconnect at any time.